Hemophilia Federation of America will host Part 2 of its advocacy call on April 30th at 6:30 pm ET
Message from the Hemophilia Federation of America: The fight to protect the bleeding disorders community is far from over, and we need YOU. Join HFA’s Advocacy Network Organizing Call Wednesday, April 30 | 6:30 PM ET https://www.hemophiliafed.org/…/next-steps-advocacy… This isn’t just
Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE®
Important Community Notice from the Hemophilia Foundation of Maryland Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE® Takeda has announced its decision to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. Takeda recognizes the significant
FDA Approves Subcutaneous Therapy for Hemophilia Patients with Inhibitors
January 2, 2025 The U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A
**Important Announcement**
As funding becomes increasingly limited, we must recognize the specialty pharmacies that partner with HFM and financially support our mission. Their partnership and contributions enable us to host events and programs such as Summer Camp, the Milton Doug Hiteshew Scholarship
Hemophilia Foundation of Maryland (HFM)
13 Class Court Parkville, MD 21234
